Regeneron's (REGN) Eylea has been approved by FDA

Regeneron's FDA approval of Eylea represents a significant advancement in the treatment of major eye diseases, which could enhance the product's market position and drive revenue growth.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

US 30-year fixed mortgage rate 6.46% (prev. 6.38%); highest since early September 2025, via Freddie Mac

Atlanta Fed GDPNow Model (Q1): 1.6% (prev. 1.9%)

Regeneron's (REGN) Eylea has been approved by FDA

Iran's Mobarakeh steel plant halts productions, Nour News reports

Cheniere Energy's (LNG) Sabine Pass LNG plant is taking on reduced flows of natgas, LSEG data shows; at least one LNG train pass is down, as Co. performs maintenance work

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • EYLEA HD® Approved by FDA as First and Only Injectable Anti-VEGF With Dosing Intervals up to 5 Months for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Context

The long dosing interval may differentiate it from competitors, potentially positioning Regeneron favorably in the biotech sector moving forward. This news could also attract investor attention to REGN, reflecting positively on the broader equities market in biotech.

Related headlines

The whole workspace, free to try.

Try it free